Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Trial of RPTR-1-201, a T Cell Receptor Bispecific Therapy, in Advanced Solid Tumors
Conditions
Interventions
RPTR-1-201
PD-1 / PD-L1 monoclonal antibody
Locations
1
United States
START Midwest
Grand Rapids, Michigan, United States
Start Date
December 12, 2025
Primary Completion Date
December 15, 2028
Completion Date
April 15, 2029
Last Updated
February 17, 2026
NCT06658951
NCT06717750
NCT06380309
NCT07292402
NCT07050641
NCT07045454
Lead Sponsor
Repertoire Immune Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions